Tag: patient information

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

The Department of Health – Abu Dhabi and Abbot Unite to Manufacture Pharmaceuticals Locally in Abu Dhabi

Reinforcing Abu Dhabi's position as a global life science hub ABU DHABI, UAE, June 20, 2025 /PRNewswire/ -- During BIO International Convention in Boston USA,...

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

Oracle Health Community Care Improves Care in Mobile, Home, and Rural Settings

The mobile technology enables access to vital patient information regardless of network connectivity and location AUSTIN, Texas, June 17, 2025 /PRNewswire/ -- Oracle today...

Johnson & Johnson Launches New TECNIS Odyssey Next-Generation Intraocular Lens in Europe, the Middle East, and Canada Offering Cataract Patients Precise Vision at Every...

The new full visual range*1 IOL enables 93% of patients to become free from glasses at all distances.**2 *** With best-in-class image contrast and low-light performance,#~3,4,5...

U.S. Food and Drug Administration Approves CSL’s ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All...

ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacksOnce-monthly dosing reduced HAE attacks by a...

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Shelby Dermatology d/b/a Dermatologists of Birmingham Clients Whose Data May Have Been...

NEWTOWN, Pa., June 11, 2025 /PRNewswire/ -- The law firm of Edelson Lechtzin LLP is investigating data privacy claims regarding an incident at Shelby...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsPatient information

《The 36th Golden Melody Awards》

Form 8.5 (EPT/RI) – Dowlais Group plc

ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT Q2 2025

Tag: patient information

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The Department of Health – Abu Dhabi and Abbot Unite to Manufacture Pharmaceuticals Locally in Abu Dhabi

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Oracle Health Community Care Improves Care in Mobile, Home, and Rural Settings

Johnson & Johnson Launches New TECNIS Odyssey Next-Generation Intraocular Lens in Europe, the Middle East, and Canada Offering Cataract Patients Precise Vision at Every...

U.S. Food and Drug Administration Approves CSL’s ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All...

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Shelby Dermatology d/b/a Dermatologists of Birmingham Clients Whose Data May Have Been...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us